If you have been reading about glucagon receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility | Soluble in water and aqueous buffers | Typical peptide behavior |
| Typical storage temperature | -20 C or below | For lyophilized material |
| Common analytical method | Reverse-phase HPLC | Purity assessment |
| Detection technique | Mass spectrometry | Identity confirmation |
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Key components of natural product synthesis include retrosynthetic analysis, which involves planning synthetic routes by working backward from the target molecule to design the most effective construction pathway. Stereochemical control is crucial to ensure the correct three-dimensional arrangement of atoms, critical for the molecule's functionality. Reaction optimization enhances yield, selectivity, and efficiency, making synthetic steps more practical. Finally, scale-up considerations allow researchers to adapt lab-scale syntheses for larger production, expanding the accessibility of synthesized products. This evolving field continues to fuel advancements in drug development, materials science, and our understanding of the diversity in natural compounds.
=== Discontinued === Acamprosate controlled-release (SNC-102) – various actions [46] ALTO-202 – NMDA receptor antagonist [47] Balovaptan (RG-7314; RO-5028442; RO-5285119) – vasopressin V1 receptor antagonist [48] Brexpiprazole (Lu-AF41156; OPC-34712; Rexulti) – atypical antipsychotic (non-selective monoamine receptor modulator) [49] Carvedilol (Coreg) – α1-, β1-, and β2-adrenergic receptor antagonist and dual alpha/beta blocker [50] Crinecerfont (Crenessity; NBI-74788; SSR-125543) – corticotropin releasing factor receptor 1 (CRF1R) antagonist [51] ENX-105 – dopamine D2 and D3 receptor agonist, dopamine D4 receptor agonist, and serotonin 5-HT1A and 5-HT2A receptor agonist [52] Fluoxetine (Prozac, Sarafem) – selective serotonin reuptake inhibitor [53] Ganaxolone (GNX; CCD-1042; Ztalmy) – GABAA receptor positive allosteric modulator and neurosteroid [54] JZP-150 (PF-04457845; PF-4457845; PF-’845) – fatty acid amide hydrolase (FAAH) inhibitor [55] Nabiximols (tetrahydrocannabinol/cannabidiol; THC/CBD; GW-1000; JZP-378; Nabidiolex®/Tetranabinex®; Sativex) – cannabinoid receptor modulator, other actions [56] Naloxone/tianeptine (TNX-601) – combination of tianeptine (weak and atypical μ-opioid receptor agonist) and naloxone (orally inactive opioid receptor antagonist) Nepicastat (APL-1401; SYN-117) – dopamine β-hydroxylase (DBH) inhibitor [57] NYX-783 – NMDA receptor modulator [58] Orvepitant (GW-823296, GW823296X) – neurokinin NK1 receptor antagonist [59] Pomaglumetad methionil (DB103; LY-2140023; LY-2812223; LY-404039 prodrug) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (pomaglumetad prodrug) [60] PRAX-114 – GABA modulator [61] PRX-3140 (PRX-03140; NTC-942) – serotonin 5-HT4 receptor agonist [62] Verucerfont (GSK-561679; NBI-77860) – corticotropin releasing factor receptor 1 (CRF1R) antagonist [63]
Pierogi, however, require complete immersion, followed by the removal of excess liquid—a significant technological challenge both in terms of the freeze-drying process and the preparation of the dish on board the ISS. While hot water can be added from a dispenser, there is no way to dispose of the leftover liquid. To solve this, freeze-dried vegetable broth was added to the pouch, allowing astronauts to first drink the broth in which the pierogi rehydrated and then enjoy the main dish. NASA's Advanced Food Technology Project (AFT) is researching ways to ensure an adequate food supply for long-duration space exploration missions. This research is primarily focused on mitigating the adverse health effects caused by long duration spaceflight. The impact to health can include symptoms such as weight loss, dehydration, a reduction in red blood cell count, constipation and electrolyte imbalances. The Advanced Food Technology Project aims to develop space foods that minimize these adverse effects.
Sources: en.wikipedia.org
MEB-1170 is an atypical opioid receptor modulator which is under development for the treatment of pain and opioid use disorder. It is a highly biased agonist of the μ-opioid receptor (MOR) and appears to be biased for activation of G protein signaling over β-arrestin recruitment. Aside from the fact that it is a MOR biased agonist, the drug is said to be a MOR full agonist as well as a κ-opioid receptor (KOR) partial agonist and to have a unique pharmacological profile. It is taken orally. The drug produces robust analgesia in several assays similarly to morphine in rodents. However, in contrast to other MOR agonists like morphine and oliceridine, MEB-1170 is said to have not produced analgesic tolerance, sedation, respiratory depression, rewarding effects, or reinforcing effects and to have shown only minimal withdrawal symptoms. In addition, unlike morphine, but similarly to oliceridine, it negligibly affected gastrointestinal transit, a measure of constipation-like effect. As such, the drug is claimed to have greatly improved tolerability, safety, and misuse liability relative to conventional opioids like morphine. The toxicokinetics of MEB-1170 in rats and dogs have been described. It has a longer duration than morphine in rodents. MEB-1170 was first described in the news media in 2017 and in the scientific literature in 2018. It is being developed by Mebias Discovery. As of April 2023, the drug is in phase 1 clinical trials for treatment of pain and opioid use disorder. It is being developed for both prevention and treatment of opioid use disorder.
Americold Realty Trust, Inc. is an American temperature controlled warehousing and transportation company based in Atlanta, Georgia, United States. It is in the business of modern commercialized temperature controlled warehousing for the storage of perishable goods via a cold chain, one of the forms of food preservation. Americold is the 2nd largest temperature-controlled warehousing and distribution services provider in the world.
=== Negative effects === However, there are concerns regarding the role of movies in shaping the younger individual's perceptions of defining mental illness. Previous research regarding the film One Flew Over the Cuckoo's Nest (1975) with college students found that the portrayal of mental illness can negatively influence the individual's attitudes regarding individuals with mental illness, psychiatric institutions, and associated factors, leading to discrimination and general lack of opportunity for work, housing, and finding community for those experiencing mental illness. The public's misconception of certain mental illnesses poses a more significant threat than their negative opinions and judgments of those with issues with mental health. It may alter their ability to recognize signs and symptoms of certain mental illnesses in themselves or people they know if they are not consistent with the image they have come to know and recognize through media. Many people believe that the mental health content in mass media is checked by professionals for accuracy and, therefore, safe to believe and gather conclusions from. However, as many television shows do no such thing, people are led to believe inaccurate portrayals. Furthermore, mass media's depiction of mental illnesses causing violent or dangerous behavior may lead the public to believe that mentally ill people are more likely to harm others than in reality. This phenomenon can lead to the public being less likely to help or visit friends and family who are experiencing mental illness.
== History == ELGA Products Limited was founded in 1937 by Walter Lorch to manufacture domestic electrical appliances, but moved into water purification to overcome the problem of limescale deposits in steam irons. It developed a small cartridge-type deionizer to purify the water. ELGA collaborated with the London School of Pharmacy to develop products aimed at the hospital market, laboratories and general industry. A manufacturing unit was set up in 1959 in Lane End, Buckinghamshire, UK. During the 1960s ELGA became a global supplier of water purification systems. ELGA Group PLC was incorporated in 1984 and became part of Protean PLC in 1992. Protean PLC was acquired by Culligan Water Technologies (Northbrook Illinois) in 1997. Culligan was acquired by U.S. Filter (Palm Springs, California) in 1998. ELGA became part of USF Limited in 1999. U.S. Filter was acquired by Vivendi S.A. (Paris, France) in 2000. ELGA became part of Vivendi Water Systems Limited and then Veolia Water Systems LTD, part of the Veolia Group, in 2003. ELGA has added North American and Asian manufacturing operations to the original UK site.
Sources: en.wikipedia.org
== Philanthropy == McGregor is involved in charity work, including UNICEF UK since 2004 and GO Campaign. During the Long Way Round journey in 2004, McGregor and his travelling companions saw some of UNICEF's work in Ukraine, Kazakhstan, and Mongolia, and during the Long Way Down trip in 2007, he and Charley Boorman did some work for UNICEF in Africa. McGregor hosted the annual Hollywood gala for the GO Campaign in 2009 and 2010. He has worked with the Children's Hospice Association Scotland, as featured in Long Way Down. In 2012, he travelled with UNICEF immunisation workers to remote parts of India, Nepal and the Republic of Congo for a BBC2 documentary entitled Ewan McGregor: Cold Chain Mission. In June 2015, McGregor read Hans Christian Andersen's "The Little Match Girl" for the children's fairy tales app GivingTales in aid of UNICEF, together with other prominent figures such as Sir Roger Moore, Stephen Fry, Dame Joan Collins, Joanna Lumley, and Sir Michael Caine.
Amphetamine also has a slight analgesic effect and can enhance the pain relieving effects of opioids. FDA-commissioned studies from 2011 indicate that in children, young adults, and adults there is no association between serious adverse cardiovascular events (sudden death, heart attack, and stroke) and the medical use of amphetamine or other ADHD stimulants. These findings were subsequently corroborated by a 2022 meta-analysis that sampled nearly four million participants, which found no association between therapeutic use of amphetamine and the development of cardiovascular disease in any age group. However, amphetamine pharmaceuticals are contraindicated in individuals with preexisting cardiovascular disease.
88H Cargo Specialist 88K Watercraft Operator 88L Watercraft Engineer 88M Motor Transport Operator 88N Transportation Management Coordinator 88P Railway Equipment Repairer (RC) 88T Railway Section Repairer (RC) 88U Railway Operations Crew Member (RC) 88Z Transportation Senior Sergeant
== Adverse effects == The safety profile of oliceridine is similar to other opioids. As with other opioids, the most common side effects of oliceridine are nausea, vomiting, dizziness, headache and constipation. Prolonged use of opioid analgesics during pregnancy can result in neonatal opioid withdrawal syndrome. Olinvyk carries a boxed warning about addiction, abuse and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; and risks from concomitant use with benzodiazepines or other central nervous system depressants. Unlike other opioids for intravenous administration, Olinvyk has a maximum recommended daily dose limit of 27 milligrams.
== Impact on settlement patterns in the United States of America == The development of refrigerated transportation changed the geography of food production and distribution in the United States by allowing perishable agricultural products to be transported over greater distances. This contributed to the development of agricultural regions farther from major eastern markets and established transport routes.
Sources: en.wikipedia.org
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.
Yes. Peptide material degrades faster at higher temperatures and under repeated handling. Lyophilized powder is typically kept cold, while reconstituted solutions have shorter usable windows. Actual recommendations depend on the specific formulation and supplier documentation.
Reliable purity assessment requires instruments such as chromatographs and mass spectrometers. Visual inspection cannot confirm identity or purity. Certificates of analysis provide supplier-reported data but do not replace independent testing.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.